Close Menu

BioMérieux

Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.

For the second quarter, sales for its clinical applications jumped nearly 14 percent, while industrial applications fell 7 percent year over year.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

The panel tests for 23 pathogens covering 19 viruses, including SARS-CoV-2, and four bacteria that are responsible for the most frequent respiratory infections.

The firm expects organic revenue growth of approximately 11 percent at constant exchange rates compared to the second quarter last year.

A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.

The test is validated and authorized for numerous extraction technologies and PCR instruments.

The panel is designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens.

First quarter revenue growth was driven by "unprecedented demand" for molecular biology products for use in COVID-19 testing.

The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.